Aslan completes Taiwanese IPO

Cancer company Aslan Pharmaceuticals Ltd. (TPEx:6497) raised NT$992 million ($33 million) through the sale of about 14.5 million shares at NT$68.92 in an IPO on the Taipei Exchange. The company said on May 16 that it had sold 10.4 million shares by auction, and said on May 24 it had sold another 2.6 million shares in a public lottery. Aslan told BioCentury the company sold an additional 1.4 million shares to employees and other investors...